OpGen is a medicine company using molecular diagnostics and informatics to help combat infectious disease. Co.'s Acuitas molecular diagnostic tests provide microbial identification and antibiotic resistance gene information, which include Co.'s Acuitas antimicrobial resistance, Gene Panel (Urine) test for patients at risk for urinary tract infections. Co.'s Acuitas Lighthouse informatics systems are cloud-based Health Insurance Portability and Accountability Act compliant informatics offerings that combine clinical lab test results with patient and hospital information to provide analytics to help manage multidrug-resistant microorganisms in the hospital and patient care environment. The OPGN stock yearly return is shown above.
The yearly return on the OPGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OPGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|